Cogstate Ltd (ASX:CGS) Stock Price, Trades & News

Cogstate Ltd is a cognitive science company. The principal activity of the group is the Creation, validation, and commercialisation of digital brain health assessments; and the Design and provision of quality assurance services in clinical trials, focused on the administration, scoring, and recording of conventional brain health assessments and reporting. Its operating segment includes Clinical Trials, Healthcare, and Administration. The company generates maximum revenue from the Clinical Trials segment. In the clinical trials segment, technology and services are sold to pharmaceutical and biotechnology companies. The company derives revenue from the sale of licensed software and cognitive testing services.

Financial Strength

9/10

Name	Current	Vs Industry
Cash-To-Debt	82
Equity-to-Asset	0.76
Debt-to-Equity	0.01
Debt-to-EBITDA	0.02
Interest Coverage	222.57
Piotroski F-Score	8/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	13.12	Distress Grey Safe
Beneish M-Score	-2.51	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

10/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	7.4
	3-Year EBITDA Growth Rate	12.4
	3-Year EPS without NRI Growth Rate	14.5
	3-Year FCF Growth Rate	14
	3-Year Book Growth Rate	17.3
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	25.02
	Future 3-5Y Total Revenue Growth Rate Estimate	18.19

Momentum Rank

1/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	53.9
	9-Day RSI	58.09
	14-Day RSI	59.17
	3-1 Month Momentum %	14.35
	6-1 Month Momentum %	15.38
	12-1 Month Momentum %	47.83

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	3.97
	Quick Ratio	3.97
	Cash Ratio	2.65
	Days Sales Outstanding	82.11
	Days Payable	65.44

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	Dividend Yield %	0.72
	Dividend Payout Ratio	0.21
	Forward Dividend Yield %	0.72
	5-Year Yield-on-Cost %	0.73
	3-Year Average Share Buyback Ratio	0.9
	Shareholder Yield %	1.5

Profitability Rank

7/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	55.74
	Operating Margin %	19.13
	Net Margin %	20.15
	EBITDA Margin %	32.17
	FCF Margin %	6.43
	OCF Margin %	16.56
	ROE %	22.26
	ROA %	16.55
	ROIC %	32.8
	3-Year ROIIC %	-88.07
	ROC (Joel Greenblatt) %	492.84
	ROCE %	27.08
	Years of Profitability over Past 10-Year	6
	Moat Score	4
	Tariff Resilience Score	9

GF Value Rank

3/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	29.37
	Forward PE Ratio	22.62
	PE Ratio without NRI	29.37
	Shiller PE Ratio	112.14
	Price-to-Owner-Earnings	28.95
	PEG Ratio	0.28
	PS Ratio	5.95
	PB Ratio	6.1
	Price-to-Tangible-Book	7.89
	Price-to-Free-Cash-Flow	92
	Price-to-Operating-Cash-Flow	35.84
	EV-to-EBIT	19.59
	EV-to-Forward-EBIT	18.6
	EV-to-EBITDA	16.03
	EV-to-Forward-EBITDA	11.49
	EV-to-Revenue	5.17
	EV-to-Forward-Revenue	4.38
	EV-to-FCF	80.09
	Price-to-GF-Value	1.35
	Price-to-Projected-FCF	4.06
	Price-to-Median-PS-Value	1.66
	Price-to-Peter-Lynch-Fair-Value	1.23
	Price-to-Graham-Number	3.25
	Price-to-Net-Current-Asset-Value	9.2
	Price-to-Net-Cash	18.4
	Earnings Yield (Greenblatt) %	5.11
	FCF Yield %	1.12
	Forward Rate of Return (Yacktman) %	21.33

GF Value™: A$2.05

ASX:CGS

Warning Signs

Warning! GuruFocus detected 3 Medium warning signs with CGS. Try a 7-Day Free Trial to check it out.

Cogstate Ltd Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Cogstate Ltd Stock Events

Financials Calendars

	Event	Date	Price (A$)
	AUD 0.020000 Cash Dividend	2025-08-27	1.80 (+1.69%)
	1.00604:1 Stock Split	2006-02-27	0.10 (-4.55%)

Show

Entries

Press Release

	Subject	Date
	Medidata and Cogstate Strike Strategic Partnership Transforming Clinical Trials in Neurology with Clinical Outcome Assessment (eCOA) and Clinician Solutions Powered by AI and Advanced Analytics	2024-10-29
	THREAD AND COGSTATE PARTNER TO SUPPORT CNS RESEARCH VIA NEXT GENERATION ECOA TECHNOLOGY AND LEADING COGNITIVE TESTING SOLUTIONS	2024-07-23
	Clario and Cogstate Expand Partnership to Deliver Leading Data Collection and Data Quality Programs for Neuroscience Clinical Trials	2022-07-09
	Clario and Cogstate Expand Partnership to Deliver Leading Data Collection and Data Quality Programs for Neuroscience Clinical Trials	2022-06-29
	Clario and Cogstate Expand Partnership to Deliver Leading Data Collection and Data Quality Programs for Neuroscience Clinical Trials	2022-06-19
	Clario and Cogstate Expand Partnership to Deliver Leading Data Collection and Data Quality Programs for Neuroscience Clinical Trials	2022-06-09
	Clario and Cogstate Expand Partnership to Deliver Leading Data Collection and Data Quality Programs for Neuroscience Clinical Trials	2022-05-30
	Clario and Cogstate Expand Partnership to Deliver Leading Data Collection and Data Quality Programs for Neuroscience Clinical Trials	2022-05-20
	Innovation Investor Conference Presentations Now Available for On-Demand Viewing	2020-12-07
	Live Innovation Investor Conference & Webinar: Public Company Presentations December 3rd	2020-11-30

10/Page

Articles on Cogstate Ltd

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.